2017
Phase I study combining the aurora kinase A (AURKA) inhibitor alisertib (Ali) with mFOLFOX in gastrointestinal (GI) cancer.
Goff L, Azad N, Stein S, Whisenant J, Vaishampayan U, Hochster H, Connolly R, Weise A, LoRusso P, El-Rifai W, Berlin J. Phase I study combining the aurora kinase A (AURKA) inhibitor alisertib (Ali) with mFOLFOX in gastrointestinal (GI) cancer. Journal Of Clinical Oncology 2017, 35: 2593-2593. DOI: 10.1200/jco.2017.35.15_suppl.2593.Peer-Reviewed Original ResearchGI cancersStandard platinum-based therapyCorrelative biomarker studyDisease control rateMost frequent toxicitiesPreliminary clinical activityPlatinum-based therapyMajority of ptsEvaluable ptsStable diseaseEligible patientsFrequent toxicitiesHematologic toxicityPartial responseStandard therapyDose escalationInhibition of AURKAControl rateGastrointestinal cancerPreclinical dataClinical activityPlatinum agentsDose levelsInhibitor alisertibOptimal timing window
2011
P1-17-07: Phase II Trial of RAD001 Plus Carboplatin in Patients with Triple-Negative Metastatic Breast Cancer.
Singh J, Stein S, Volm M, Smith J, Novik Y, Speyer J, Adams S, Meyers M, Muggia F, Schneider R, Formenti S, Omene C, Choi H, Davis S, Goldberg J, Tiersten A. P1-17-07: Phase II Trial of RAD001 Plus Carboplatin in Patients with Triple-Negative Metastatic Breast Cancer. Cancer Research 2011, 71: p1-17-07-p1-17-07. DOI: 10.1158/0008-5472.sabcs11-p1-17-07.Peer-Reviewed Original ResearchTriple-negative metastatic breast cancerGrade 3 neutropeniaMetastatic breast cancerBreast cancerClinical benefitGrade 3Platinum agentsNon-hematological grade 3Negative metastatic breast cancerTriple-negative breast cancerGrade 3 thrombocytopeniaPrior chemotherapy regimensSingle-agent carboplatinDose of carboplatinPhase II trialProgression-free survivalOral mTOR inhibitorTriple-negative breast cancer cellsDifferent breast cancer cell linesPhosphorylation site-specific antibodiesNegative breast cancer cellsBreast cancer cell linesBreast cancer cellsAkt-mTOR pathwayAssessable patients